BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26329846)

  • 1. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.
    Han K; Xu X; Xu Z; Chen G; Zeng Y; Zhang Z; Cao B; Kong Y; Tang X; Mao X
    Sci Rep; 2015 Sep; 5():12809. PubMed ID: 26329846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin.
    Kwon B; Querfurth HW
    Biochimie; 2015 Nov; 118():141-50. PubMed ID: 26344902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction.
    Lee J; Shi Y; Vega M; Yang Y; Gera J; Jung ME; Lichtenstein A
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4714-4724. PubMed ID: 28916338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle.
    Joassard OR; Amirouche A; Gallot YS; Desgeorges MM; Castells J; Durieux AC; Berthon P; Freyssenet DG
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2444-55. PubMed ID: 23916784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
    Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway.
    Cao B; Li J; Zhou X; Juan J; Han K; Zhang Z; Kong Y; Wang J; Mao X
    Sci Rep; 2014 Jul; 4():5749. PubMed ID: 25034786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway.
    Zhang Z; Mao H; Du X; Zhu J; Xu Y; Wang S; Xu X; Ji P; Yu Y; Cao B; Han K; Hou T; Xu Z; Kong Y; Jiang G; Tang X; Qiao C; Mao X
    Oncotarget; 2016 Feb; 7(8):9296-308. PubMed ID: 26814430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
    Zhang H; Chen J; Zeng Z; Que W; Zhou L
    Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
    Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
    Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oridonin inhibits mTOR signaling and the growth of lung cancer tumors.
    Wang YY; Lv YF; Lu L; Cai L
    Anticancer Drugs; 2014 Nov; 25(10):1192-200. PubMed ID: 25075795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H; Frost P; Shi Y; Hoang B; Sharma S; Fisher M; Gera J; Lichtenstein A
    Cancer Res; 2006 Feb; 66(4):2305-13. PubMed ID: 16489035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.
    Tang J; Zhu J; Yu Y; Zhang Z; Chen G; Zhou X; Qiao C; Hou T; Mao X
    Oncotarget; 2014 Jun; 5(11):3836-48. PubMed ID: 25003534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GABARBP down-regulates HIF-1α expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways.
    Park SH; Kim BR; Lee JH; Park ST; Lee SH; Dong SM; Rho SB
    Cell Signal; 2014 Jul; 26(7):1506-13. PubMed ID: 24686084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.